IL202445A0 - Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro - Google Patents

Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro

Info

Publication number
IL202445A0
IL202445A0 IL202445A IL20244509A IL202445A0 IL 202445 A0 IL202445 A0 IL 202445A0 IL 202445 A IL202445 A IL 202445A IL 20244509 A IL20244509 A IL 20244509A IL 202445 A0 IL202445 A0 IL 202445A0
Authority
IL
Israel
Prior art keywords
disorders
vitro
diseases
expanded
self
Prior art date
Application number
IL202445A
Other languages
English (en)
Original Assignee
Garnet Bio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garnet Bio Therapeutics Inc filed Critical Garnet Bio Therapeutics Inc
Publication of IL202445A0 publication Critical patent/IL202445A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
IL202445A 2007-06-15 2009-12-01 Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro IL202445A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92915107P 2007-06-15 2007-06-15
US92915207P 2007-06-15 2007-06-15
US95520407P 2007-08-10 2007-08-10
US99609307P 2007-11-01 2007-11-01
PCT/US2008/007488 WO2008156728A1 (en) 2007-06-15 2008-06-16 Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro

Publications (1)

Publication Number Publication Date
IL202445A0 true IL202445A0 (en) 2011-08-01

Family

ID=40156544

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202445A IL202445A0 (en) 2007-06-15 2009-12-01 Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro

Country Status (14)

Country Link
US (5) US8354370B2 (enExample)
EP (1) EP2171043B1 (enExample)
JP (1) JP2010529987A (enExample)
KR (1) KR20100035648A (enExample)
CN (1) CN101835891A (enExample)
AP (1) AP2010005103A0 (enExample)
AU (1) AU2008266885A1 (enExample)
CA (1) CA2690143A1 (enExample)
CO (1) CO6251330A2 (enExample)
EA (1) EA201070022A1 (enExample)
IL (1) IL202445A0 (enExample)
MX (1) MX2009013672A (enExample)
NZ (1) NZ582616A (enExample)
WO (1) WO2008156728A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EA201070022A1 (ru) 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro
AU2010235362B2 (en) * 2009-04-06 2013-10-24 Industry-Academic Cooperation Foundation, Yeungnam University Method of preparing a gender-specific serum and biomarker using the serum
CN103124492A (zh) * 2010-05-28 2013-05-29 加内特生物治疗学股份有限公司 使用具有来源于体外培养和扩增的自我更新集落形成细胞的组分的有生命的和无生命的生物反应装置的组合物和方法
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
KR101548124B1 (ko) * 2011-10-04 2015-08-31 (주) 메디컬그룹베스티안 피부결함의 완화 또는 치료를 위한 세포처리 및 적용 시스템
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
US20140134732A1 (en) * 2012-11-14 2014-05-15 Wisconsin Alumni Research Foundation Simplified Compositions and Methods for Generating Neural Stem Cells From Human Pluripotent Stem Cells
GB201513996D0 (en) 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109251885A (zh) * 2018-09-26 2019-01-22 北京添易医学研究院 医美级胎盘基蜕膜干细胞内液的制备方法
CN111394306B (zh) * 2020-04-15 2023-08-01 深圳市旷逸生物科技有限公司 一种提高脐带间充质干细胞的体外扩增速率的培养方法
CN114591910B (zh) * 2022-03-28 2023-11-21 重庆市铂而斐细胞生物技术有限公司 一种利用低氧三维环境培养的间充质干细胞富集脐血造血干细胞的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1168205B (it) 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
US4609551A (en) 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4608199A (en) 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4620327A (en) 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
US5744347A (en) * 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
JPH10505250A (ja) 1994-06-06 1998-05-26 ケース ウエスターン リザーブ ユニバーシティ 組織再生のためのバイオマトリックス
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5643736A (en) 1995-02-06 1997-07-01 Osiris Therapeutics, Inc. Monoclonal antibodies for human osteogenic cell surface antigens
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5716616A (en) 1995-03-28 1998-02-10 Thomas Jefferson University Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5728581A (en) 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
WO1997024434A1 (en) 1995-12-29 1997-07-10 Alg Company Expansion of bone marrow stromal cells
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
WO1999056759A1 (en) 1998-05-07 1999-11-11 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
CA2348770A1 (en) 1998-10-26 2000-05-04 Philadelphia Health & Education Corporation Stromal cell use
US6184035B1 (en) 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
DK1183035T3 (en) 1999-05-14 2015-03-09 Ford Henry Health System BONE MARROW TRANSPLANT TREATMENT stroke
US6226914B1 (en) * 1999-06-25 2001-05-08 Waymon Burton Reed Firearm safety apparatus
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
EP1218489B1 (en) 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
CA2389488A1 (en) 1999-10-29 2001-05-17 Philadelphia Health & Education Corporation Isolation and expansion of human marrow stromal cells
FR2801979B1 (fr) 1999-12-03 2002-02-08 Oreal Utilisation d'un anticorps specifique des fibroblastes papillaires comme marqueur de qualite d'une peau
US7544509B2 (en) 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
ATE370225T1 (de) 2000-02-11 2007-09-15 Philadelphia Health & Educatio Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
US20040058418A1 (en) 2000-04-11 2004-03-25 Tetsuo Endo Alpha 1,2-fucosyltransferase and process for producing fucose-containing complex carbohydrate
ATE330001T1 (de) 2000-04-12 2006-07-15 Philadelphia Children Hospital Therapeutische verwendung mesenchymaler stromazellen
AU2001285359A1 (en) 2000-09-01 2002-03-13 Neuronyx, Inc. Novel synthetic gangliosides
WO2002034889A2 (en) 2000-10-24 2002-05-02 Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US7056738B2 (en) 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
US20030059941A1 (en) 2001-06-14 2003-03-27 Prockop Darwin J. Transduced marrow stromal cells
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
WO2004058305A2 (en) * 2002-12-24 2004-07-15 An-Go-Gen Inc. Encapsulated cell for therapy
JP2006521792A (ja) 2003-02-13 2006-09-28 国立大学法人京都大学 細胞の未分化状態マーカーならびに幹細胞の分離および調製のための組成物および方法
EP2298861B1 (en) * 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1753859B1 (en) * 2004-06-04 2014-07-30 Université Pierre et Marie Curie (Paris 6) A method for producing red blood cells
WO2005121316A1 (en) * 2004-06-11 2005-12-22 Bernard O'brien Institute Of Microsurgery Tissue material and muscle derived matrix
AU2005302469A1 (en) * 2004-10-28 2006-05-11 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
EA201070022A1 (ru) 2007-06-15 2010-06-30 Гарнет Байотерапьютикс Инк. Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro

Also Published As

Publication number Publication date
US20090053183A1 (en) 2009-02-26
AU2008266885A1 (en) 2008-12-24
EP2171043A1 (en) 2010-04-07
EP2171043B1 (en) 2015-03-18
KR20100035648A (ko) 2010-04-05
NZ582616A (en) 2012-07-27
CA2690143A1 (en) 2008-12-24
CN101835891A (zh) 2010-09-15
EA201070022A1 (ru) 2010-06-30
US20140099329A1 (en) 2014-04-10
MX2009013672A (es) 2010-03-30
JP2010529987A (ja) 2010-09-02
US20120156192A1 (en) 2012-06-21
US8354370B2 (en) 2013-01-15
US20120148544A1 (en) 2012-06-14
US20140086884A1 (en) 2014-03-27
WO2008156728A1 (en) 2008-12-24
CO6251330A2 (es) 2011-02-21
EP2171043A4 (en) 2010-08-11
AP2010005103A0 (en) 2010-02-28

Similar Documents

Publication Publication Date Title
AP2010005103A0 (en) Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
IL324279A (en) Methods for preparing human RPE cells and pharmaceutical preparations of human RPE cells
IL216283A0 (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
GB2450603B (en) Human pluripotent stem cells and their medical use
IL249102A0 (en) Melatonin tablet and methods for preparation and use
WO2008106102A9 (en) Inhibitors of rtp801 and their use in disease treatment
ZA200906061B (en) Use of copper and glutamate in cell culture for production of polypeptides
IL231449A0 (en) Humanized tissues for in-vitro research uses, their arrays, and methods for their production
PL2390255T3 (pl) Nowe aminoglikozydy i ich zastosowania w leczeniu zaburzeń genetycznych
IL193800A0 (en) Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
EP2262777B8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1
IL208579A0 (en) Methods and use of inducing a poptosis in cancer cells
ZA200907017B (en) Mutant reoviruses and methods of making and using
EP2221034A4 (en) HOLLOWED SHOULDERS FOR WEARING AND MANUFACTURING PROCESS THEREFOR
GB201002469D0 (en) Parthenote-derived stem cells and methods of making and using them
ZA201209556B (en) Compositions and methods of using living and non-living bioactive devices with components derived from self-renewing colony forming cells cultured and expanded in vitro
PL2318020T3 (pl) Immunosupresyjne komórki krwi i sposób ich wytwarzania
BRPI0813905A2 (pt) Tratamento de doenças e distúrbios usando células formadoras de colônia autorrenováveis cultivadas e expandidas in vitro
IL209604A (en) Isolated cell populations, methods for their creation and use in the treatment of central nervous system diseases
EP2129787A4 (en) Methods of gene amplification and expression
HK1166311A (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
GB0911184D0 (en) In vitro methods for the preparation of differentiated haematopoietic cells and uses thereof
IL244653A0 (en) New amino-sugars and their use for the treatment of genetic diseases
HK1143831B (en) Human pluripotent stem cells and their medical use
IL229577A0 (en) New amino-sugars and their use for the treatment of genetic diseases